ERBB2 and neoplasm: Regardless of the specific assay used, the data consistently show that a considerable proportion of women with node-negative ER-positive/HER2-negative tumours have a low risk of recurrence and derive little benefit from the addition of chemotherapy to the standard hormonal therapy [8].